Clinical Trial Update: Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating enzalutamide with Lu-PSMA-617 versus enzalutamide alone for metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Lu-PSMA-617 (lutetium-177-PSMA-617)

Snippet

Sponsor: Australian and New Zealand Urogenital and Prostate Cancer Trials Group | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: UNKNOWN